# Study of Varespladib in Patients Hospitalized With Severe COVID-19

> **NCT04969991** · PHASE2 · TERMINATED · sponsor: **Ophirex, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Coronavirus Disease 2019
- Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2

## Interventions

- **DRUG:** Varespladib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04969991
- **Lead sponsor:** Ophirex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-30
- **Primary completion:** 2022-02-11
- **Final completion:** 2022-11-22
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Part 2 of the study was paused on 03-May-2022 due to slow enrollment following low infection rates and hospitalizations of patients with severe COVID-19, and did not recommence prior to study closure (early termination) on 22-Nov-2022.
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969991, "Study of Varespladib in Patients Hospitalized With Severe COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04969991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*